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costs of $571 versus $301 for the control cohort (p < 0.0001).
CONCLUSION: Bipolar patients have signiﬁcantly more meta-
bolic co-morbidities and higher medical costs than in age- and
gender-matched controls. To reduce the medical and economic
burden of bipolar disorder, strategies should be identiﬁed to
prevent the development of metabolic co-morbidities and
improve medication adherence.
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OBJECTIVE: Obesity, a known risk factor associated with
bipolar disorder, complicates its treatment, potentially adding
signiﬁcantly to overall treatment cost. The difference in bipolar
treatment cost between obese patients and normal weight
patients has not been adequately evaluated. The purpose of this
study is to assess treatment costs and co-morbidities associated
with obesity in Medicaid patients with bipolar disorder.
METHODS: From a multi-state managed care Medicaid claims
database, a total of 13,242 patients with bipolar disorder during
the period January 1, 1998 to December 31, 2002 were selected
for this study. Patients had to be older than six years or younger
than 65 at the ﬁrst date of bipolar diagnosis. Annual treatment
cost per patient was constructed as the sum of reimbursed
amounts (in 2002 constant dollars) for hospitalizations, physi-
cian encounters, drugs, and other medical services. A log-linear
regression analysis was used to assess factors inﬂuencing annual
treatment costs. Logistic regression analysis was conducted to
assess the association between overweight and related clinical
factors. RESULTS: A total of 3192 (24.1%) were treated with
atypical antipsychotics, 1700 (12.8%) with lithium, and 4575
(34.5%) with other anticonvulsants. A total of 1064 (8.0%)
patients received an obesity or overweight diagnosis during the
study period. The average annual treatment costs were $11,780
(SD  15,290) for patients experiencing obesity and $8546
(SD  17,971) otherwise. Other major determinants of higher
treatment cost included bipolar I or NOS (p < 0.0001), being
female (p < 0.0001), the use of anticonvulsants (p < 0.0001) and
atypical antipsychotics (p < 0.0001), alcohol and substance
abuse disorder (p < 0.0001), and diabetes mellitus (p < 0.0001).
The risk of being overweight was statistically associated with
co-morbidities like anxiety disorder (odds ratio [OR] = 1.43,
95% CI: 1.25–1.64), hypertension (OR = 3.02, 95% CI: 2.54–
3.59), etc. CONCLUSION: Signiﬁcant treatment costs are asso-
ciated with obesity in patients with bipolar disorder. Metabolic
complications should be considered by clinical practitioners
when prescribing medication in this population.
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OBJECTIVE: Fewer than half of patients diagnosed with Major
Depressive Disorder (MDD) respond to the ﬁrst medication used,
but an adequate trial may take seven weeks. The BRITE-MD
study reported that a frontal quantitative EEG biomarker, Anti-
depressant Treatment Response [ATR] Index, was 74% accurate
in predicting response/no-response to escitalopram after 1 week
of treatment. The objective is to examine the economic and
quality of life consequences of early switching of medication.
METHODS: We modeled the economic and quality of life con-
sequences of using ATR to individualize treatment of MDD as a
mixed decision tree-Markov model using the seven week results
from the BRITE-MD study. Other potential beneﬁts of the tech-
nology, such as improved adherence, were not considered in this
analysis. RESULTS: The short-term model estimated an increase
of 7.1 responders at seven weeks per 100 treated patients. Based
on published utility weights for responders ranging from 0.73 to
0.78, and an average utility weight for non-responders of 0.47,
the model estimated a 10% gain in QALYs for the ATR group
over the initial 7 weeks of treatment. The incremental cost effec-
tiveness ratio for the base estimate was $11,441. Sensitivity
analysis indicated that ATR was cost saving at modest unit cost
values, and that the $50,000/QALY threshold was not reached
until the unit cost reached $179. Long-term model estimates, and
the cost effectiveness of ATR use under different treatment and
cost assumptions, along with optimized ATR performance, will
also be presented. CONCLUSION: The modeling estimates indi-
cate that the use of ATR would be a cost effective method for
individualizing care for patients with MDD. Under the assump-
tions and cost weights used in our short-term model, ATR fell
well below the $50,000 per QALY threshold for all reasonable
model assumptions, and thus met the usual benchmark for good
value for money for US economic analyses.
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OBJECTIVE: To evaluate impact of risperidone long-acting
injection (RLAI) versus oral antipsychotic treatments on hospi-
talization outcomes for patients participating in the electronic
Schizophrenia Treatment Adherence Registry (e-STAR) in Spain.
METHODS: e-STAR is a two year, multi-national, prospective,
observational study of patients with schizophrenia who were
initiated on RLAI or an oral antipsychotic. This report is based
on the ﬁnal, complete e-STAR data from Spain. Hospitalization
outcomes including number of hospitalizations and number of
days in hospital were collected retrospectively for one year and
prospectively every three months for two years. Changes in hos-
pital stays and days in hospital were compared between RLAI
patients and oral patients using a linear mixed model controlling
for age, gender, disease duration, and baseline antipsychotic use
patterns. RESULTS: A total of 1622 patients (63.6% male, mean
age 38.4  11.2 years) participated in e-STAR from Spain, 1345
were initiated on RLAI and 277 were treated with oral antipsy-
chotics. RLAI patients had signiﬁcantly longer disease duration
(12.6  9.5 years vs. 10.9  9.7 in oral patients, p < 0.01).
Average hospital stay at baseline was ﬁve days longer for RLAI
patients than oral patients. During the two year study, both
treatments showed reductions in mean number of hospitaliza-
tions and mean number of days in hospital. As revealed by
the mixed-model regression, RLAI patients, compared to oral
patients, had a signiﬁcantly greater reduction in mean number of
hospitalizations (-0.28 vs. -0.18 in followup-year1 and -0.37 vs.
-0.20 in followup-year2, p < 0.05) and mean number of days in
hospital (-17.23 vs. -12.96 in followup-year1 and -18.75 vs.
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-12.99 in followup-year2, p < 0.01). CONCLUSION: This two
year, prospective, observational study showed that compared to
oral antipsychotics, RLAI treatment was associated with greater
reduction in hospital stays and days in hospital in patients with
schizophrenia.
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OBJECTIVES: Schizophrenia care produces a substantial eco-
nomic burden. Interventions that reduce the need for resource
use are of interest to clinicians and payers. This study assessed
changes in mental health resource use following initiation of
paliperidone extended-release tablets (paliperidone ER) in the
three double-blind (DB) trials and their open-label extensions
(OLE). METHODS: A retrospective chart review generated
data on resource use during the 12 months before and after the
DB trials. Additional IRB approval and informed consent were
obtained for these reviews. Average number of inpatient and
ambulatory care services in the pre- and post-periods was cal-
culated, including use of bootstrap resampling methods to
assess statistical signiﬁcance of differences. Total person years
were calculated for the pre- and post-periods to account for
different lengths of observation. Separate analyses were also
performed by country. RESULTS: In this analysis, patients
(n = 79) were from the United States (38.0%), Canada (19.0%)
and Malaysia (43.0%). Mean (SD) patient age was 38.0
(10.4) years; and the majority of patients were male (73.4%).
Most (70.9%) patients received prior treatment with antipsy-
chotics. During the OLE, the mean paliperidone ER treatment
duration (SD) was 226.4 (142.3) days, and the mean dose
was 11.5 (2.2) mg. Overall, paliperidone ER patients used
fewer resources after drug initiation (mean reduction per
person year: days hospitalized = 12.1, p = 0.002; number of
emergency room visits = 0.3, p = 0.038; number of psychiatric-
related ofﬁce visits = 2.3, p < 0.001; number of psychotherapy
sessions = 0.4, p = 0.004). Subgroup analyses revealed that the
greatest reduction in most resource categories was found in the
US sites (e.g. mean reduction in days hospitalized per person
year = 19.7 in the US, 6.3 in Canada, and 7.1 in Malaysia).
CONCLUSIONS: In this post-hoc analysis, paliperidone ER
was associated with a statistically signiﬁcant reduction in
mental health resource use. Prospective studies are needed to
conﬁrm the ﬁndings.
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OBJECTIVE: To compare health care resource utilization and
costs of Major Depressive Disorder (MDD) adult patients
treated with escitalopram 10 mg who increase to 20 mg vs.
those who were switched to a SNRI. METHODS: Adult MDD
patients initiated on escitalopram 10 mg who either increased
to 20 mg escitalopram or switched to a SNRI were identiﬁed in
the IHCIS National Managed Care Database (2003–2006).
Patients who changed therapy within 60 days from escitalo-
pram initiation date (index date) were excluded. Outcomes
included rates of hospitalization and emergency visits, number
of emergency visits days, and health care costs, and were
reported for all cause and MDD-related. All outcomes were
estimated over a 3 months period post-therapy change (dose
increase or switching) and were descriptively compared
between the two groups. Multivariate regression analyses were
performed to further adjust for patient demographics, comor-
bidities and baseline health care resource use. RESULTS: Study
samples included 9379 patients who increased escitalopram
from 10 mg to 20 mg and 1215 patients who were switched
from 10 mg escitalopram to a SNRI. Compared to patients
who increased escitalopram dose, SNRI switchers experienced
higher rates of MDD-related hospitalizations (RR = 1.2,
p = 0.566), higher rates of MDD-related emergency visit
(RR = 1.6, p < 0.05), and higher number of emergency visit
days (RR = 1.5, p < 0.01) in the 3-month post-therapy change
period. Patients who switched to SNRI also had on average
$413 higher total costs (p < 0.001), which include $390 higher
drug costs (p < 0.001). Results from multivariate regression
analyses were consistent with ﬁndings from descriptive analy-
ses. SNRI switchers incurred $430 higher risk-adjusted total
costs (p < 0.0001). CONCLUSION: Compared to adult MDD
patients who increased escitalopram from 10 mg to 20 mg,
patients who switched to a SNRI had more MDD-related emer-
gency visits, as well as higher drug and total health care costs
during the 3-month post-therapy change period.
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OBJECTIVE: Acute psychiatric hospitalizations represent a
major cost driver of care for psychiatric disorders. This analysis
characterized the costs of psychiatric hospitalization in the United
States bymajor psychiatric disorders and payer type.METHODS:
The analysis utilized Premier’s Perspective database of de-
identiﬁed inpatient administrative claims. Data from 263,252
psychiatric hospitalizations were classiﬁed into: Schizophrenia,
Bipolar Disorder, Depression, Substance Use, and Other Psychi-
atric Disorder based on All Patient Reﬁned—Diagnosis Related
Group codes. Results were inﬂated to national estimates by
weighting each hospitalization based on representative demo-
graphics of all hospitals in the nation. Because reimbursed values
were not available, the primary metric for analyses was the cost of
providing service rather than charges.RESULTS:The total cost of
all psychiatric hospitalizations in 2006 dollars was $10.6 billion
with charges of $26.5 billion. Public payers covered most psychi-
atric hospitalizations, particularly for schizophrenia with a much
smaller difference for bipolar disorder, depression, and substance
use disorders. Length of stay was longest for schizophrenia (11.0
days) followed by bipolar disorder (7.8 days), depression (6.2
days), and substance use disorders (5.0 days). Regardless of
disorder, length of stay was longer for public payers (8.7 days)
than private payers (5.6 days) or self-pay (4.6 days). The average
per daywas inversely related to length of stay with the highest cost
for substance use disorders ($1034) followed by depression
($888), bipolar disorder ($852), and schizophrenia ($806).CON-
CLUSION: The cost of delivering care for psychiatric hospitaliza-
tions in the US was approximately $10.6 billion in 2006. This
estimate does not include some physicians fees and does not
capture the amount reimbursed to the hospitals. Althoughmost of
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